ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23% Market Closed
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ESSA Pharma Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Interest Income Expense
$5.9m
CAGR 3-Years
164%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bright Minds Biosciences Inc
CNSX:DRUG
Interest Income Expense
-CA$5.6k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Interest Income Expense
-$10.1m
CAGR 3-Years
-19%
CAGR 5-Years
-21%
CAGR 10-Years
-52%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Interest Income Expense
$12.6m
CAGR 3-Years
182%
CAGR 5-Years
7%
CAGR 10-Years
21%
Covalon Technologies Ltd
XTSX:COV
Interest Income Expense
-CA$56.9k
CAGR 3-Years
58%
CAGR 5-Years
27%
CAGR 10-Years
1%
Spectral Medical Inc
TSX:EDT
Interest Income Expense
-CA$11m
CAGR 3-Years
-281%
CAGR 5-Years
-226%
CAGR 10-Years
-101%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.86 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is ESSA Pharma Inc's Interest Income Expense?
Interest Income Expense
5.9m USD

Based on the financial report for Sep 30, 2024, ESSA Pharma Inc's Interest Income Expense amounts to 5.9m USD.

What is ESSA Pharma Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
164%

Over the last year, the Interest Income Expense growth was 6%. The average annual Interest Income Expense growth rates for ESSA Pharma Inc have been 164% over the past three years .

Back to Top